Scarica l'app Stockscreener
9.88
4.45%
-0.46
Pre-mercato:
9.88
Upstream Bio Inc Borsa (UPB) Ultime notizie
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
Bull Bear: Is Upstream Bio Inc a cyclical or defensive stock2026 Intraday Action & Low Drawdown Trading Strategies - baoquankhu1.vn
UPB Options Volatility — NASDAQ:UPB - TradingView — Track All Markets
UPB Options Chain — NASDAQ:UPB - TradingView — Track All Markets
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward - TipRanks
Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Earnings Update: Is Upstream Bio Inc still a buy after recent gains2026 Rallies & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Truist cuts Upstream Bio stock price target on trial timeline By Investing.com - Investing.com Canada
Market Recap: Is Upstream Bio Inc forming a bullish divergence2026 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Piper Sandler Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Upstream Bio, Inc. (UPB) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Retail Surge: Does Upstream Bio Inc have a sustainable dividendTrade Signal Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
UpStream Bio | 10-K: FY2025 Annual Report - Moomoo
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen - MarketBeat
VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors - TipRanks
Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line - MarketBeat
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $15 to $42 - moomoo.com
Evercore ISI cuts Upstream Bio stock rating on lack of near-term catalysts - Investing.com India
Evercore ISI cuts Upstream Bio stock rating on lack of near-term catalysts By Investing.com - Investing.com South Africa
Evercore ISI Downgrades Upstream Bio to In Line From Outperform, Adjusts PT to $15 From $40 - marketscreener.com
Upstream Bio, Inc. Enters At-the-Market Sales Agreement with Leerink Partners LLC for Common Stock Offering - Minichart
Upstream Bio Announces Positive Phase 2 Results and Phase 3 Strategy for Verekitug in Severe Asthma and CRSwNP, Financials Support Operations Through 2027 - Minichart
Upstream Bio plans Phase 3 trials for asthma drug in Q1 2027 By Investing.com - Investing.com South Africa
Upstream Bio plans Phase 3 trials for asthma drug in Q1 2027 - Investing.com India
According to the latest filing with the SEC, biotechnology company Upstream Bio Inc has entered into a sales agreement with Leerink Partners LLC and plans to raise up to 150 millions dollars by publicly offering common shares. - Bitget
Upstream Bio enters $150 million at-the-market sales agreement with Leerink Partners - Investing.com
Upstream Bio Launches $150 Million At-The-Market Program - TipRanks
Upstream Bio (NASDAQ: UPB) files ATM to raise up to $150M via Leerink - Stock Titan
Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program - Stock Titan
Upstream Bio (NASDAQ: UPB) advances verekitug for severe asthma, CRSwNP and COPD - stocktitan.net
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors - TipRanks
Why Is Upstream Bio Stock Trading Higher Today?Upstream Bio (NASDAQ:UPB) - Benzinga
Will Upstream Bio Inc outperform during market ralliesQuarterly Growth Report & AI Forecasted Stock Moves - baoquankhu1.vn
Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Upstream Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
UPB: Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027 - TradingView
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Upstream Bio, Inc. unveils financial results and sets Phase 3 path for verekitug - tradersunion.com
Upstream Bio Q4 net loss widens on higher R&D costs - TradingView
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy - Stock Titan
Upstream Bio (NASDAQ:UPB) Trading Up 11.2%What's Next? - MarketBeat
Gainers Report: Is Upstream Bio Inc still a buy after recent gains2026 Valuation Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Upstream Bio, Inc.(NasdaqGS: UPB) dropped from S&P Biotechnology Select Industry Index - MarketScreener
Aug EndMonth: What is the next catalyst for Upstream Bio IncMarket Trend Report & Stock Timing and Entry Methods - baoquankhu1.vn
UPB SEC FilingsUpStream Bio Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Upstream Bio Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
UPB | Upstream Bio, Inc. Common Insider Trading - Quiver Quantitative
Upstream Bio CFO Gray sells $7915 in shares By Investing.com - Investing.com India
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):